Home Featured

Featured

BREAKING: State of Kentucky Sets aside $42 Million for Psychedelic Research, with Focus on Ibogaine

Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office for Repirinast and the Treatment of CKD

COMPASS Pathways’ Co-Founder Ekaterina Malievskaia to Step Down as Chief Innovation Officer

Psychedelic Bulletin #138: Delix’s Non-Hallucinogenic Psychedelic Enters the Clinic; Arizona Earmarks $5m for Whole Mushroom Psilocybin Trials; MEPs form EU Action Group

Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21

PT412 – Psychedelics and Virtual Reality: Where Novel Experience, Technology, and...

Numinus to research COMP360 psilocybin therapy in treatment-resistant depression as part...

FILAMENT HEALTH ANNOUNCES INTERIM RESULTS FROM PHASE I CLINICAL TRIAL AT...

COMPASS Pathways to participate in upcoming Jefferies Healthcare Conference

Psychedelics Weekly – New LSD Research and The Challenges Facing a...

Terran Biosciences announces new breakthroughs in the chemistry of MDMA and...

Sunstone Therapies presents data at ASCO showing positive long-term follow-up results...

Data Demonstrating Long-Term Improvement in Depression in Cancer Patients Following Single...

Small Pharma Announces Significant Developments In Intellectual Property Portfolio

Numinus Aligns Business Initiatives to Prepare for Future Approval of MDMA-Assisted...

12 3...215 Page 1 of 215

BREAKING: State of Kentucky Sets aside $42 Million for Psychedelic Research,...

Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office...

COMPASS Pathways’ Co-Founder Ekaterina Malievskaia to Step Down as Chief Innovation...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

William Leonard Pickard participating in celebration for Sasha Shulgin’s new book...

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.